Partner With Us NRI

Natco Pharma Ltd share Price

Company details

6M Return 10.36%
1Y Return -7.12%
Mkt Cap.(Cr) 11,291.24
Volume 545,569
Div Yield 0.89%
OI Chg %
Volume 545,569

Open Free Trading Account Online with ICICIDIRECT

Steady performance; focus shifts to crop protection…

About The Stock

    Natco has, over the years, developed a knack for manufacturing complex generic products with few competitors, especially for the US market.

    • India formulations mainly comprise oncology products (38 brands). For the US, it follows partnership products for risky launches and acquired Dash Pharma for front-end presence. It has six FDF, two API manufacturing facilities and two crop health sciences units
    • Maiden entry into crop protection was via launch of pheromone product, Natmate PBW for controlling pink bollworm in cotton
    • FY22 revenue break-up - domestic business: 25%, international business: 62% (mainly from the US), APIs: 13%


    Revenues were buoyed by gains from gRevlimid, in the export formulation segment while Natco booked inventory write-off for Covid products of
    ₹ 232 crore and provisioning towards estimated credit loss of ₹ 46 crore.

    • Sales were up 80% YoY to ₹ 597 crore
    • Adjusted EBITDA for one-offs was at ₹ 259 crore, with margins at 43%
    • Booked loss of ₹ 50 crore vs. profit of ₹ 53 crore in Q4FY21

Click here for full recommendation

Research view on more stocks

Natco Pharma Ltd.

Q4FY23 Quarterly & FY23 Annual Result Announced for Natco Pharma Ltd.

Pharmaceuticals company Natco Pharma announced Q4FY23 & FY23 results:

  • Consolidated total revenue of Rs 2,811.7 crore for FY23, as against Rs 2,043.8 crore for FY22, reflecting 37.6% growth.
  • The net profit for FY23, on a consolidated basis, was Rs 715.3 crore, as against Rs 170.0 crore in FY22.
  • The increase in revenue and profits for FY23 was driven by business growth in the US market and growth in our subsidiaries in Canada & Brazil. Our Crop Health Division started off well with strong growth potential in ensuing years.
  • For Q4FY23, the company recorded a net revenue of Rs 926.9 crore, on a consolidated basis, as against Rs 610.6 crore during Q4FY22.
  • The profit for Q4FY23 on a consolidated basis was Rs 275.8 crore, as against a loss of Rs 50.5 crore in Q4FY22.



Result PDF

View Other Company Results


Investment recommendation

Steady performance; focus shifts to crop protection…
Call Date
15 Feb 2023
Entry Price 530.00
Target Price 565.00
12-18 Month


Operating Profit
Profit after Tax
Reserves and Surplus
Operating Profit
Profit after Tax

Natco Pharma Ltd Stocks COMPARISION


Equity Capital: 4,263.60 Cr FV: 2.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 2,333.12 37,369.27
LAST 3M 16,668.82 53,102.69
LAST 6M 64,410.78 32,565.35
LAST 12M 119,684.93 75,969.00
Natco Pharma Limited - Related Party Transactions

May 29, 2023 l NSE Announcement

NSE Board Meetings Forthcomming

May 29, 2023 l NSE Board Meetings Forthcomming

Board Meeting for Today

May 29, 2023 l Board Meetings for Today

Date Action Type Ratio
Feb 21, 2023 Dividend 62.5
Nov 21, 2022 Dividend 37.5
Aug 19, 2022 Dividend 175

Natco Pharma Ltd Information

Stock PE (TTM)
Promoter Holding
Book Value
  • NATCO is an Indian pharmaceutical company that manufactures and markets various pharmaceutical drugs, healthcare products, and chemical formulations. The company also provides chemical manufacturing services on a contract basis. NATCO is headquartered in Hyderabad. In addition to India, NATCO has operations in Canada, Australia, the Philippines, Brazil, and other countries. The company is known as a major producer of cancer-related medicines and drugs for treating Hepatitis-C.

    On 19 December 2022, the market capitalisation of the company was Rs 10,041.56 crore. It reported consolidated sales of Rs 351.1 crore at the end of September 2022. The company is listed on the Bombay Stock Exchange with the code 524816 and the National Stock Exchange with the code NATCOPHARM.

    On 30 September 2022, the company’s shareholding pattern indicated a promoter stake of 48.8%, a 0% stake of foreign institutional investors, and DIIs held a stake of 14.3%, and the public held a stake of 36.9% in the company. The company’s shareholding pattern has remained largely consistent over the past year, with the exception that the FII stake in the company has gone down from around 20% to nil. 

    The company’s board of directors comprises GS Murthy, VC Nannapenni, Rajeev Nannapenni, P S R K Prasad, D G Sharaf, Leela Digumarti, MUR Naidu, and T V Rao, Pavan Bhatt, and others. The auditors are B S R & Associates LLP. On 30 September 2022, the company had a total of 18.26 crore shares outstanding.

    On 19 December 2022, NATCO Ltd.’s share price on BSE was Rs 550.10 and Rs 550 on NSE. The share price touched a 52-week high of Rs 944 and a 52-week low of Rs 545. Its three-month return to investors was -13.56%, while its one-year return was -34.8%.

    As of November 2022, Mirae Asset Emerging Bluechip Direct-Growth had invested Rs 207.7 crore in the company, while ICICI Pru Value Discovery Direct-G and Mirae Asset Midcap Fund Direct-G had invested Rs 163.9 and Rs 116.6 crore, respectively. 

    The company’s peers include Ajanta Pharma, Suven Pharma, and Glenmark Pharma.

    Disclaimer: ICICI Securities Ltd. (I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is a Member of National Stock Exchange of India Ltd (Member Code: 07730), BSE Ltd (Member Code: 103) and Member of Multi Commodity Exchange of India Ltd.(Member Code: 56250) and having SEBI registration no. INZ000183631. Name of the Compliance officer (broking): Ms. Mamta Shetty, Contact number: 022-40701022, E-mail address: complianceofficer@icicisecurities.com. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Such representations are not indicative of future results. The securities quoted are exemplary and are not recommendatory. Investors should consult their financial advisers if in doubt about whether the product is suitable for them. The contents herein above are solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments or any other product. Investors should consult their financial advisers whether the product is suitable for them before taking any decision. The contents herein mentioned are solely for informational and educational purpose.

Registered Address

Natco House, Road No 2 Banjara Hills, Hyderabad, Telangana, 500033

Tel : 91-040-23547532
Email : investors:natcopharma.co.in
Website : http://www.natcopharma.co.in

Venture Capital & Corp. Inv.

AGM Date (Month) : Oct
Face Value Equity Shares : 2
Market Lot Equity Shares : 1
BSE Code : 524816
Book Closure Date (Month) :
BSE Group : A
ISIN : INE987B01026

FAQ’s on Natco Pharma Ltd Shares

You can buy Natco Pharma Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Natco Pharma Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of May 31, 2023 03:59 PM the closing price of Natco Pharma Ltd was ₹ 618.80.

Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of May 31, 2023 03:59 PM, the market cap of Natco Pharma Ltd stood at ₹ 11,291.24.

The latest PE ratio of Natco Pharma Ltd as of May 31, 2023 03:59 PM is 15.78

The latest PB ratio of Natco Pharma Ltd as of May 31, 2023 03:59 PM is 0.43

The 52-week high of Natco Pharma Ltd is ₹ 778.90 while the 52-week low is ₹ 502.00

According to analyst recommendations, Natco Pharma Ltd has a “Buy” rating for the long term.

Download Our App

market app
market app